- Home
- NCPL vs CERO Comparison
NCPL vs CERO Comparison
Compare NCPL & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- CERO
- Stock Information
- Founded
- NCPL 1984
- CERO 2017
- Country
- NCPL United States
- CERO United States
- Employees
- NCPL N/A
- CERO N/A
- Industry
- NCPL Investment Managers
- CERO
- Sector
- NCPL Finance
- CERO
- Exchange
- NCPL Nasdaq
- CERO Nasdaq
- Market Cap
- NCPL 4.3M
- CERO 3.5M
- IPO Year
- NCPL N/A
- CERO N/A
- Fundamental
- Price
- NCPL $6.58
- CERO $8.80
- Analyst Decision
- NCPL
- CERO Strong Buy
- Analyst Count
- NCPL 0
- CERO 2
- Target Price
- NCPL N/A
- CERO $45.00
- AVG Volume (30 Days)
- NCPL 850.8K
- CERO 3.3M
- Earning Date
- NCPL 07-28-2025
- CERO 08-13-2025
- Dividend Yield
- NCPL N/A
- CERO N/A
- EPS Growth
- NCPL N/A
- CERO N/A
- EPS
- NCPL N/A
- CERO N/A
- Revenue
- NCPL $812,612.00
- CERO N/A
- Revenue This Year
- NCPL N/A
- CERO N/A
- Revenue Next Year
- NCPL $101.16
- CERO N/A
- P/E Ratio
- NCPL N/A
- CERO N/A
- Revenue Growth
- NCPL N/A
- CERO N/A
- 52 Week Low
- NCPL $1.41
- CERO $6.71
- 52 Week High
- NCPL $11.90
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- NCPL 63.58
- CERO 46.05
- Support Level
- NCPL $5.70
- CERO $9.10
- Resistance Level
- NCPL $7.31
- CERO $9.73
- Average True Range (ATR)
- NCPL 1.16
- CERO 1.50
- MACD
- NCPL 0.13
- CERO -0.02
- Stochastic Oscillator
- NCPL 62.27
- CERO 8.63
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.